目的 探討復(fù)方鮮竹瀝液聯(lián)合福多司坦治療慢性阻塞性肺疾病急性加重期的臨床效果。方法 選取2018年4月—2019年6月天津市寶坻區(qū)人民醫(yī)院收治的慢性阻塞性肺疾病急性加重期患者82例，隨機(jī)分成對(duì)照組（41例）和治療組（41例）。對(duì)照組餐后口服福多司坦片，0.4 g/次，3次/d。治療組在對(duì)照組的基礎(chǔ)上口服復(fù)方鮮竹瀝液，20 mL/次，3次/d。兩組患者均連續(xù)治療14 d。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者臨床表現(xiàn)緩解時(shí)間、自我評(píng)估測(cè)試（CAT）問(wèn)卷評(píng)分、肺功能，以及痰上清液和血清中腫瘤壞死因子-α（TNF-α）、白介素-8（IL-8）、基質(zhì)金屬蛋白酶-9（MMP-9）、轉(zhuǎn)化生長(zhǎng)因子-β（TGF-β）水平。結(jié)果 治療后，對(duì)照組和治療組臨床有效率分別為80.48%和95.12%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組患者肺部哮鳴音及咳、痰、喘的緩解時(shí)間較對(duì)照組顯著縮短（P<0.05）。治療后，兩組患者CAT問(wèn)卷評(píng)分、殘氣容積與肺總量比值（RV/TLC）均顯著降低（P<0.05），而第1秒用力呼氣容積（FEV1）占預(yù)計(jì)值%、最大呼氣中期流量（MMEF）及FEV1與用力肺活量比值（FEV1/FVC）顯著升高（P<0.05），且治療組上述指標(biāo)改善效果明顯優(yōu)于對(duì)照組（P<0.05）。治療后，兩組痰上清液和血清中TNF-α、IL-8、MMP-9、TGF-β水平顯著降低（P<0.05），且治療組上述各項(xiàng)指標(biāo)水平均較對(duì)照組顯著降低（P<0.05）。結(jié)論 復(fù)方鮮竹瀝液聯(lián)合福多司坦治療慢性阻塞性肺疾病急性加重期有利于迅速穩(wěn)定患者病情，改善肺通氣功能，整體療效確切。

Objective To investigate the clinical effect of Compound Xianzhuli Liquid combined with fidostatin in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients (82 cases) with acute exacerbation of chronic obstructive pulmonary disease in Tianjin Baodi Hospital from April 2018 to June 2019 were randomly divided into control (41 cases) and treatment (41 cases) groups. Patients in the control group were po administered with Fludostam Tablets, 0.4 g/time, three times daily. Patients in the treatment group were po administered with Compound Xianzhuli Liquid on the basis of the control group, 20 mL/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the remission time of clinical manifestation, CAT questionnaire scores, lung function, TNF-α, IL-8, MMP-9, and TGF-β in sputum supernatants and serum in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 80.48% and 95.12% respectively, and there were differences between two groups (P<0.05). After treatment, the remission time of pulmonary wheezing, cough, phlegm and asthma in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the CAT questionnaire scores, RV/TLC in two groups were significantly decreased (P<0.05), but the FEV 1% accounting for predicted value, MMEF and FEV1/FVC were significantly increased (P<0.05), and the indicators in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the level of TNF-α, IL-8, MMP-9 and TGF-β in sputum supernatants and serum in two groups was significantly decreased (P<0.05), and the level of these indicators in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Compound Xianzhuli Liquid combined with fidostatin in treatment of acute exacerbation of chronic obstructive pulmonary disease is beneficial to rapidly stabilize the patient's condition and improve lung ventilation function, which has exact overall effect.

R974